Legend Biotech wins FDA IND clearance for dual-target in vivo CAR-T

Legend Biotech has secured US Food and Drug Administration clearance of an investigational new drug application for LB2501, its in vivo CAR-T candidate targeting both CD19 and CD20 in patients with relapsed or refractory B-cell malignancies. The clearance paves the way for a planned US Phase 1/2 study assessing safety, tolerability, pharmacokinetics, and preliminary efficacy.

The NASDAQ-listed company says LB2501 is the first dual-targeting in vivo CAR-T therapy known to have received FDA IND clearance. That claim has not been independently verified, though the in vivo modality as a whole remains early-stage, with few programmes globally at an equivalent regulatory juncture.

How LB2501 works

Unlike conventional autologous CAR-T products, which require extracting a patient's T cells, engineering them outside the body, and reinfusing them weeks later, LB2501 is administered as a single, off-the-shelf infusion. It relies on Legend's proprietary TaVec platform: an engineered, replication-incompetent lentiviral vector that selectively transduces T cells in the circulation, prompting them to express a chimeric antigen receptor directed at both CD19 and CD20. The dual-target design is intended to reduce the risk of antigen escape, a common mechanism by which B-cell malignancies develop resistance to CD19-only therapies. Notably, Legend says LB2501 is being evaluated without lymphodepleting chemotherapy, a pre-conditioning step that adds toxicity and logistical complexity to standard CAR-T regimens.

A parallel Phase 1, open-label study in China (NCT07002112) is already underway in relapsed or refractory B-cell malignancy patients, providing early safety and tolerability signals that may inform the US programme design.

Ingrid Zhang, chief executive of Legend Biotech, said the clearance represents "an important step in advancing LB2501 and our broader in vivo cell engineering platform," adding that the company is working to "simplify access to and delivery of this important treatment class."

Market and competitive context

The in vivo CAR-T field is attracting significant attention from developers who view it as a potential answer to the access, cost, and manufacturing bottlenecks that have constrained the uptake of approved ex vivo products. Treatments such as CARVYKTI, Legend's own approved multiple myeloma CAR-T developed with Johnson and Johnson, require sophisticated manufacturing infrastructure and carry list prices running to hundreds of thousands of pounds per course; a vein-to-vein in vivo approach, if validated clinically, could substantially reduce those barriers.

Several other companies, including a number of venture-backed and university-spinout groups, are pursuing in vivo T-cell engineering across oncology and autoimmune indications, using lentiviral, adeno-associated virus, and lipid nanoparticle delivery systems. The competitive dynamic will hinge on which platform first demonstrates durable responses with an acceptable safety profile, particularly given that lentiviral vectors carry insertional mutagenesis risks that regulators will scrutinise carefully in Phase 1.

B-cell non-Hodgkin lymphoma accounts for around 90% of all malignant lymphomas, and patients who relapse after multiple lines of therapy have historically faced limited options. Even incremental progress in this setting can support a meaningful commercial opportunity. The US Phase 1/2 study will be watched closely for signs that LB2501 can replicate or improve upon the response rates seen with approved CD19-directed and CD19/CD22 bispecific therapies, and for any safety differentiation from lymphodepletion-free dosing.